Tonn J C, Schachenmayr W, Kraemer H P
Department of Neurosurgery, University of Würzburg, Germany.
Anticancer Res. 1994 May-Jun;14(3B):1371-5.
Tumor specimens of malignant human gliomas were processed in a colony forming assay (CFA, n = 70) and a metabolic test system (MTT-test, n = 49) for in-vitro chemosensitivity testing. The clinical data as well as the complete follow-up of these patients were obtained until their death or at least 2 years of survival. By means of multivariate statistical analysis we demonstrate that both test systems are not influenced by biometrical data of the patient of histopathological parameters of the tumor. According to the COX regression model the results of both assays are per se no prognostic factor when regarded independently of additional treatment. However, in 33 patients treated with either ACNU or BCNU, a prospective correlative trial clearly demonstrates a predictive value of the CFA in adjuvant chemotherapy of gliomas.
对恶性人脑胶质瘤的肿瘤标本进行了集落形成试验（CFA，n = 70）和代谢测试系统（MTT试验，n = 49），以进行体外化疗敏感性测试。获取了这些患者的临床数据以及完整的随访信息，直至他们死亡或至少存活2年。通过多变量统计分析，我们证明这两种测试系统均不受患者生物统计学数据或肿瘤组织病理学参数的影响。根据COX回归模型，当独立于额外治疗进行考虑时，两种检测方法的结果本身均不是预后因素。然而，在33例接受ACNU或BCNU治疗的患者中，一项前瞻性相关性试验清楚地证明了CFA在胶质瘤辅助化疗中的预测价值。
